Somapacitan in children born small for gestational age: a randomized controlled phase 3 trial

Key Points

• The aim is to evaluate the efficacy and safety of somapacitan compared to daily growth hormone in children born small for gestational age.
• Conducted a randomized controlled trial
• Assessed efficacy, safety, and tolerability after 52 weeks of treatment
• Compared somapacitan with daily growth hormone (GH)
• Somapacitan showed similar efficacy to daily GH
• Safety and tolerability profiles were comparable
• Potentially reduces treatment burden, improving adherence